Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Urol. 2008 Feb;26(1):67-74. doi: 10.1007/s00345-007-0234-z. Epub 2008 Jan 4.

Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform.

Author information

  • 1Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany.

Abstract

INTRODUCTION:

Bladder cancer (BCa) is one of the most prevalent malignancies worldwide, mostly due to its high recurrence rates. In consequence, the necessity of repeated screening for reappearance demonstrates the urgent need for novel biomarkers as alternatives to invasive standard procedures.

METHODS:

Proteomic technologies have emerged as powerful platforms for unbiased biomarker discovery and revolutionized the classical "target-driven" analysis of single marker candidates. Although proteome profiling is still far from demonstrating its full potential in clinical diagnosis, first studies clearly denote its significant potential.

CONCLUSIONS:

This review provides a discussion of the challenges related to clinical proteomics using mass spectrometry, emphasizing bladder cancer biomarker discovery. An outline of the technological prerequisites for reliable proteome profiling, data mining and interpretation, as well as, reflections on future trends in the field are provided.

PMID:
18175124
DOI:
10.1007/s00345-007-0234-z
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center